Chapter 6

Heritability and the genetic correlation of heart rate variability and blood pressure in >29 000 families: the Lifelines Cohort Study

Balewgizie S Tegegne, Tengfei Man, Arie M van Roon, Harriëtte Riese, Ilja M Nolte, Harold Snieder

Hypertension 2020;76(4)
Abstract

Dysregulation of the cardiac autonomic nervous system, as indexed by reduced heart rate variability (HRV), has been associated with the development of high blood pressure (BP). However, the underlying pathological mechanisms are not yet fully understood. This study aimed to estimate heritability of HRV and BP and to determine their genetic overlap. We used baseline data of the three-generation Lifelines population-based cohort study (n=149,067, mean age=44.5). In-house software was used to calculate root mean square of successive differences and SD of normal-to-normal intervals as indices of HRV based on 10-second resting ECGs. BP was recorded with an automatic BP monitor. We estimated heritabilities and genetic correlations with variance components methods in ASReml software. We additionally estimated genetic correlations with bivariate linkage disequilibrium score regression using publicly available genome-wide association study data. The heritability (SE) estimates were 15.6% (0.90%) for SD of normal-to-normal intervals and 17.9% (0.90%) for root mean square of successive differences. For BP measures, they ranged from 24.4% (0.90%) for pulse pressure to 30.3% (0.90%) for diastolic BP. Significant negative genetic correlations (all P<0.0001) of RMSSD/SDNN with systolic BP (-0.20/-0.16) and with diastolic BP (-0.15/-0.13) were observed. LD score regression showed largely consistent genetic correlation estimates of root mean square of successive differences/SD of normal-to-normal intervals with systolic BP (range: -0.08 to -0.23) and diastolic BP (range: -0.20 to -0.27). Our study shows a substantial contribution of genetic factors in explaining the variance of HRV and BP measures in the general population. The significant negative genetic correlations between HRV and BP indicate that genetic pathways for HRV and BP partially overlap.

Keywords: heritability, genetic correlation, heart rate variability, blood pressure, Lifelines
Introduction

Heart rate variability (HRV), reflecting beat-to-beat fluctuations in heart rate over time\(^1\), has emerged as one of the most widely used noninvasive indices of cardiac autonomic nervous system function. The imbalance of the autonomic cardiovascular control plays a key role in the risk for high blood pressure (BP)\(^2\). The modulation of vagal tone helps to maintain the dynamic autonomic function necessary for short term BP regulation. More specifically, sympathetic inhibition reduces peripheral resistance, while parasympathetic activation attenuates heart rate and contractility. Conversely, sympathetic activation and subsequent parasympathetic inactivation allows the baroreflex to elevate BP\(^3\). Both cross-sectional\(^4\) and prospective\(^5,6\) studies have shown associations between low HRV and high BP, suggesting an essential role of lower HRV in the development of hypertension.

Besides the established demographic\(^7\) and lifestyle factors\(^8\) that have been reported to explain the individual differences in HRV level at rest, numerous studies have shown that genetic factors contribute substantially to the variance. For example, Sinnreich and colleagues reported heritability estimates of 41% and 39% for SDNN and RMSSD, respectively based on 5 minutes Holter recordings in the Kibbutzim family study\(^9\). Recent investigations from the Oman Family Study\(^10,11\) reported heritability estimates of 12.3% to 20.5% from 10 minutes electrocardiogram recordings in a supine position. In twin studies, the genetic contribution to individual differences in HRV measures can be as high as 74%\(^12,13\). Likewise, previous studies reported that individual differences in BP traits, such as systolic BP (SBP), diastolic BP (DBP), and pulse pressure (PP), could for a large part be accounted for by genetic factors\(^14\). In a meta-analysis of published twin studies, Wang and colleagues reported that the pooled heritability of SBP, DBP, and PP were 54%, 49%, and 50%, respectively\(^15\). Family-based studies from Switzerland\(^16\), Oman\(^10,17\), and the Seychelles\(^18\) reported heritability estimates ranging from 19% to 24% for SBP, 5% to 25% for DBP, and 18% to 37% for PP.

Although the studies mentioned above have shown the contribution of genetic factors for individual variation in HRV and BP, heritability estimates were from relatively small samples. Moreover, most of these studies did not correctly adjust for the well-known and recently more recognized effect of heart rate on HRV\(^19\). Thus, large population-based family studies are needed for better understanding of the genetic effects.
Additionally, although an association between HRV and hypertension was found in many epidemiological studies, the underlying pathophysiological mechanisms are not yet fully understood. Given that HRV and BP are both heritable, we hypothesized that shared genetic factors may partly explain the negative association between the 2 traits. In this study, we aimed to (1) determine the genetic contributions to individual differences in both HRV and BP and (2) to estimate the magnitude of any potential genetic overlap between HRV and BP. We used data from the population-based Lifelines Cohort Study and Biobank\textsuperscript{20}, which with its 3-generation family design, large sample size, and broad age range, is ideally suited for this study.

**Methods**

**Data availability**

The data that were used in this study are available from the Lifelines Cohort Study and Biobank (research@lifelines.nl) upon reasonable request. Lifelines is a facility that is open for all researchers, information on application and data access procedures is available on https://www.lifelines.nl/researcher/how-to-apply.

**Study setting and population**

The Lifelines Cohort Study and Biobank, with >167000 participants, is a large population-based prospective study in the northern part of The Netherlands, aiming to investigate risk factors for multifactorial diseases. The design and cohort profile of the Lifelines study have been described before\textsuperscript{20,21}. In short, baseline data were collected between 2006 and 2013. The recruitment of the Lifelines study was family-based by design. Eligible participants between 20 and 50 years of age were invited to participate through their general practitioners. After the inclusion of these individuals, their partner, children, parents and partner’s parents were also invited to participate in the study. In addition, single individuals could register for participation online. In this way, a 3-generation family study was realized. Subsequently, we used the information on family members as well as information on (anonymized) names and birth dates of parents provided by all participants in questionnaires to define relationships between undefined family members in Lifelines. For instance, 2 sibs could participate in Lifelines and obtained different family IDs, if they were invited by their respective spouses. This process resulted in 40496 singletons (i.e., individuals without any relative in the sample) and 30914 families (of size $\geq 2$) of up to 4 generations with an average family size of 4.12. The largest family connected 189 participants. Spouses without children were considered as a family of size 2, even though they are genetically
unrelated. Figure 1 shows an example of 23 member Lifelines family extending over 4 generations.

During the baseline visit, electrocardiogram (ECG) recordings were obtained from 153,793 participants (91.8%) aged 13 years and above. From these, HRV could not be calculated in 4,586 participants due to excessive noise and ectopic (non-sinus node) beats and 140 were excluded due to extreme values (< or >5SD from the mean) for either HRV or BP measures. In the current analysis, 149,067 individuals (1.03% children; 96.5% European ancestry) with age range of 13-94 were included, of which 40,955 were singletons. The remaining individuals belonged to a total of 29,107 families with an average family size of 3.71. The largest family connected 169 participants.

All participants signed an informed consent. The Lifelines cohort study is conducted according to the principles of the declaration of Helsinki and following the research code of University Medical Center Groningen and approved by its medical ethical committee.

**Figure 1:** An example of a 23-member Lifelines pedigree extending over 4 generations. Numbers: Lifelines subject identifications; squares: men and circles: women; gray: founders.

**Measurements**

A 10-second 12-lead resting electrocardiogram (ECG) was recorded while participants were in a supine resting position. For the ECG recording, CardioPerfect software (Welch Allyn DT100 recorder, Welch Allyn, Skaneateles Falls, NY) was used. From the 12-leads, 4 (I, II, V4 and V5) were selected to detect R-peaks in the ECG. The details of HRV calculation in Lifelines have been published previously7.
In short, ECG recordings were excluded from HRV calculation if (1) the number of beats were <5, (2) the ratio between maximal and minimal inter-beat interval (IBI) exceeded 1.4 indicating a missing trigger or extrasystolic beat, (3) there was extremely low variability (defined as the SD of IBI <1.2 ms), or (4) <60% of the recording time was included in the calculation. In-house software was used to calculate the RMSSD and SDNN as indices of HRV, which are used in the present study. Heart rate has a well-established strong inverse relationship with HRV, which includes a mathematical dependency of the variance in IBI on the mean IBI that is unrelated to the underlying biology. Our group has reintroduced a recommended approach to correct HRV for its dependency on the mean IBI of consecutive R-peaks using coefficients of variation\textsuperscript{19,22}. The coefficient of variation detects the amount of IBI variability relative to the mean IBI of each participant. We applied this method to additionally calculate HRV values that were corrected for the influence of mean IBI. Heart rate was calculated from the ECG recording using $60 \times \frac{1000}{\text{mean IBI}}$.

Simultaneously with the ECG recordings, BP was measured with an automatic BP monitor (DinaMap, PRO 100V2) every minute during 10 minutes while the participant was in a supine resting position. The mean of the last 3 measures was used to calculate SBP and DBP. For participants taking antihypertensive medication (see below), we corrected the measured BP values by adding 15mmHg for SBP and 10mmHg for DBP\textsuperscript{23}. From the adjusted BP values, PP and mean arterial pressure (MAP) were calculated as $PP = SBP - DBP$ and $MAP = \frac{(2 \times DBP + SBP)}{3}$.

Medications and diseases that have been reported to influence HRV were included as covariates. Participants self-reported prescription during the baseline visit, which were classified according to the Anatomical Therapeutic Chemical classification, were used to define medications. A list of Anatomical Therapeutic Chemical codes prescribed to treat hypertension, depression, type 2 diabetes, and cardiovascular diseases in the Netherlands were retrieved from the Dutch Pharmacotherapeutic Compass (https://www.farmacotherapeutischkompas.nl). Participants were considered to have cardiovascular disease if they self-reported one of the following diseases: (1) heart failure, atrial fibrillation, vascular diseases (myocardial infarction, stroke, aneurysm) and (2) if participants used medications related to these symptoms (β-blockers, angiotensin-converting enzyme inhibitors, diuretics, vitamin K antagonist, statins, aspirin, and clopidogrel). Any participant who had either self-reported type 2 diabetes, use of anti-diabetes medication(s), a fasting blood glucose $\geq 7.0$ mmol/L, or HbA1c $\geq 6.5\%$ was considered to have type 2 diabetes. Hypertension was defined as having SBP $\geq 140$ mmHg or DBP $\geq 90$.
Heritability and the genetic correlation of heart rate variability and blood pressure in >29 000 families

Statistical analysis
The baseline characteristics of participants, stratified by sex, were described as mean and SD for continuous traits and as percentages for categorical variables. A natural logarithmic transformation was computed to achieve approximate normality of HRV indices. ANOVA and Chi-square tests were used to compare any differences between men and women.

Heritability estimate
Heritability is defined as the proportion of phenotypic variation explained by the genetic differences of individuals in a population. For the univariate analyses, we assumed a linear mixed model for the heritability analysis as follows:

\[ y = Xb + Za + Zf + e \]

where \( y \) is a vector of the response variable (HRV or BP); \( b \) is the vector of regression coefficients for the fixed effects, \( a \), additive genetic effects with variance \( \sigma^2_A \); \( f \), family (shared environment) effects with variance \( \sigma^2_f \); and \( e \), residuals (environmental effects) with variance \( \sigma^2_e \). \( X \) is the design matrix of the fixed effects, \( Z_a \) is the design matrix mapping subjects to the genetic kinship (relationship) matrix \( A \), and \( Z_f \) is the design matrix for family (group) effects. There are no known genetic relationships between individuals in different families.

Once the total and phenotypic variances were estimated from the linear mixed model, narrow-sense heritability was calculated as,

\[ h^2 = \frac{\sigma^2_a}{\sigma^2_a + \sigma^2_f + \sigma^2_e} \]

where \( \sigma^2_a \) is the additive genetic variance, \( \sigma^2_f \) is the shared environmental variance, and \( \sigma^2_e \) is the residual (environmental) variance. The singletons were included in the analysis and contributed to the estimations of variances and phenotypic correlations but not to the genetic correlations.

Genetic correlation estimate
The genetic correlations were estimated using the same designs and similar methods as used to estimate heritability in an expanded set of equations (i.e., a bivariate model). In the bivariate analyses, the genetic correlations between HRV and BP were obtained from the estimated additive genetic covariance and variance components as:

\[ r_G = \frac{\sigma_{A_xA_y}}{\sqrt{\sigma^2_{A_x} \sigma^2_{A_y}}} \]

where \( \sigma_{A_xA_y} \) is the additive genetic covariance between trait x and trait y and \( \sigma^2_{A_x} \) and \( \sigma^2_{A_y} \) are the additive genetic variance for traits x and y, respectively.

To test the significance of the \( h^2 \) estimates (\( h^2 > 0 \)) and genetic correlations (\( |r_G| > 0 \)), mmHg or use of antihypertensive medication. Body mass index was calculated as weight/height squared and expressed in kg/m².
the model in which all variances and correlations were estimated was compared, using a Likelihood Ratio Test, to a model in which additive genetic variances and genetic correlations for all measures were constrained to be zero. Similarly, genetic correlations were constrained to be equal to 1 or -1 to test the presence of complete overlap of genetic effects ($|r_G|=1$). In all analyses, the fixed effects (or covariates) included age, sex, and body mass index. Age squared was also added to the model, to accommodate the curvilinear relationship of HRV with age. In further analyses, heritability estimates of HRV indices were adjusted for a history of diseases (cardiovascular disease, hypertension and type 2 diabetes) and antidepressant use. We did not include smoking and alcohol use as additional covariates in our models as we have previously shown that the influence of these lifestyle factors on HRV was negligible. Here we also confirmed for BP that addition of these lifestyle factors as covariates to the model only had minimal impact on heritability estimates (Table S1 in the Data Supplement). We report proportion of variance explained by these covariates. The analyses were performed using ASReml 4.1 software. ASReml is a statistical package that fits the linear mixed models using Restricted Maximum Likelihood (REML) to estimate the variance components.

We additionally estimated the genetic correlations using bivariate linkage disequilibrium score regression on the latest publicly available genome-wide association study summary statistics for HRV and BP.

**Results**

Characteristics of the participants are provided in Table 1. Men had a lower heart rate. Means of RMSSD and SDNN were significantly higher in women than in men, and the difference remained significant after correcting the values for mean IBI. In general, all BP measures were significantly higher in men, and women had a lower BMI. The prevalence of hypertension and type 2 diabetes was higher in men, but no sex difference was seen for cardiovascular diseases. The proportion of antidepressants use was significantly higher in women.

Table 2 shows the proportion of phenotypic variances explained by additive genetic factors, shared family environment, and covariates for different traits. Heart rate showed a heritability of 22.7%. The univariate narrow-sense heritability estimates for the HRV indices ranged from 13.4% to 17.9%. Correcting them for the mean IBI slightly lowered $h^2$ estimates for both RMSSD and SDNN. The $h^2$
Heritability and the genetic correlation of heart rate variability and blood pressure in >29 000 families

estimates for BP measures ranged from 24.4% for PP to 30.3% for DBP. SBP and MAP showed heritability estimates of 28.0% and 30.1%, respectively.

Table 1: Characteristics of Study Participants and the Distribution of Heart Rate Variability and Blood Pressure Measurements for Men and Women Separately

<table>
<thead>
<tr>
<th>Variables</th>
<th>Total (N=149067)</th>
<th>Men (n=61625)</th>
<th>Women (n=87442)</th>
<th>P Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>European ancestry, n (%)</td>
<td>143,892 (96.5)</td>
<td>59,535 (96.6)</td>
<td>84,357 (96.5)</td>
<td>≤0.001</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>25.99 (4.36)</td>
<td>26.29 (3.74)</td>
<td>25.79 (4.74)</td>
<td>≤0.001</td>
</tr>
<tr>
<td>Type 2 diabetes mellitus, n (%)</td>
<td>4221 (2.8)</td>
<td>2153 (3.5)</td>
<td>2068 (2.4)</td>
<td>≤0.001</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>48,602 (32.6)</td>
<td>22,061 (35.8)</td>
<td>26,541 (30.4)</td>
<td>≤0.001</td>
</tr>
<tr>
<td>Cardiovascular disease, n (%)</td>
<td>9358 (6.3)</td>
<td>3964 (6.4)</td>
<td>5394 (6.2)</td>
<td>0.238</td>
</tr>
<tr>
<td>Antidepressant use, n (%)</td>
<td>7842 (5.3)</td>
<td>1993 (3.2)</td>
<td>5849 (6.7)</td>
<td>≤0.001</td>
</tr>
<tr>
<td>Heart rate, bpm</td>
<td>67.30 (11.0)</td>
<td>65.81 (11.18)</td>
<td>68.35 (10.76)</td>
<td>≤0.001</td>
</tr>
<tr>
<td>RMSSD, ms</td>
<td>37.31 (31.60)</td>
<td>34.43 (29.87)</td>
<td>39.34 (32.61)</td>
<td>≤0.001</td>
</tr>
<tr>
<td>lnRMSSD, ln(ms)</td>
<td>3.35 (0.73)</td>
<td>3.27 (0.73)</td>
<td>3.42 (0.72)</td>
<td>≤0.001</td>
</tr>
<tr>
<td>RMSSDc, %</td>
<td>3.97 (3.08)</td>
<td>3.57 (2.86)</td>
<td>4.24 (3.21)</td>
<td>≤0.001</td>
</tr>
<tr>
<td>lnRMSSDc, ln(%)</td>
<td>1.15 (0.66)</td>
<td>1.04 (0.66)</td>
<td>1.23 (0.65)</td>
<td>≤0.001</td>
</tr>
<tr>
<td>SDNN, ms</td>
<td>36.14 (26.40)</td>
<td>34.69 (25.91)</td>
<td>37.15 (26.73)</td>
<td>≤0.001</td>
</tr>
<tr>
<td>lnSDNN, ln(ms)</td>
<td>3.36 (0.67)</td>
<td>3.32 (0.69)</td>
<td>3.40 (0.66)</td>
<td>≤0.001</td>
</tr>
<tr>
<td>SDNNc, %</td>
<td>3.91 (2.70)</td>
<td>3.68 (2.62)</td>
<td>4.07 (2.74)</td>
<td>≤0.001</td>
</tr>
<tr>
<td>lnSDNNc, ln(%)</td>
<td>1.16 (0.63)</td>
<td>1.09 (0.65)</td>
<td>1.22 (0.62)</td>
<td>≤0.001</td>
</tr>
<tr>
<td>SBP,† mm Hg</td>
<td>126.78 (16.76)</td>
<td>131.66 (15.42)</td>
<td>123.34 (16.82)</td>
<td>≤0.001</td>
</tr>
<tr>
<td>DBP,† mm Hg</td>
<td>74.59 (10.25)</td>
<td>77.33 (10.36)</td>
<td>72.65 (9.72)</td>
<td>≤0.001</td>
</tr>
<tr>
<td>MAP, mm Hg</td>
<td>91.98 (11.61)</td>
<td>95.44 (11.21)</td>
<td>89.55 (11.27)</td>
<td>≤0.001</td>
</tr>
<tr>
<td>PP, mm Hg</td>
<td>52.19 (11.41)</td>
<td>54.32 (10.66)</td>
<td>50.69 (11.68)</td>
<td>≤0.001</td>
</tr>
</tbody>
</table>

Means (SD) are shown unless indicated otherwise. BMI indicates body mass index; BP, blood pressure; DBP, diastolic blood pressure; In, logarithmic transformation; lnRMSSDc, log-transformed corrected root mean square of successive differences; lnSDNN, log-transformed SD of normal-to-normal intervals; lnSDNNc, log-transformed corrected SD of normal-to-normal intervals; MAP, mean arterial pressure; PP, pulse pressure; RMSSD, root mean square of successive differences; RMSSDc, corrected root mean square of successive differences; SBP, systolic blood pressure; SDNN, SD of normal-to-normal intervals; and SDNNc, corrected SD of normal-to-normal intervals.

*Age-adjusted P value.
†BP values were corrected for antihypertensive use.

In addition to the additive genetic influence, we calculated the proportions of variance explained by shared family environment and covariates of HRV, heart rate and BP measures. The shared family environment contributed 4.5% of the variance for heart rate. The contribution of familial environmental effects to the variance of HRV was negligible. With regard to BP, we found small effects of the shared family environment that ranged from 0.9% for PP to 3.2% for MAP. The percentage of variance explained by the covariates was 18.4% for SDNN and 19.8% for RMSSD.
These contributions even became slightly larger, 20.9%, and 23.7%, respectively, when the effect of mean IBI was taken into account. Similarly, the result showed a substantial contribution of covariates for BP that ranged from 19.0% for PP to 28.3% for SBP. The included covariates explained only 2.6% of the percentage of variance for heart rate.

In Table 3 the bivariate genetic, phenotypic, and environmental correlations between HRV and BP are shown. We found a significant genetic correlation of -0.60 between RMSSD and heart rate and -0.53 between SDNN and heart rate. These correlations were reduced to -0.38 and -0.22 respectively when HRV values were corrected for the effect of mean IBI. There were negative genetic correlations between RMSSD and BP-related traits with a correlation of -0.20 with SBP, -0.15 with DBP, -0.18 with MAP and -0.14 with PP, that were consistent significantly different from 0. Similarly, there were slightly smaller but significantly consistent correlations between SDNN and the BP measures. However, the correlation between SDNN and pulse pressure was not statistically significant. When repeating the analyses with HRV measures corrected for the mean IBI, phenotypically HRV and BP measures still showed negative correlations (ranging from -0.05 to -0.07) with the highest correlation observed between corrected RMSSD and SBP, but
they were smaller than for the uncorrected HRV values. Nevertheless, most genetic correlations remained significantly different from zero. All genetic correlations were significantly different from 1. The bivariate linkage disequilibrium score regression largely confirmed direction and magnitude of our results based on the Lifelines pedigree data with estimates of $r_G$ with RMSSD and SDNN ranging from -0.08 to -0.23 for SBP and -0.20 to -0.27 for DBP (Table 4).

**Table 3:** Bivariate Quantitative Genetic Analyses of HR Variability with HR and Blood Pressure Examining the Genetic, Phenotypic, and Environmental Correlations

<table>
<thead>
<tr>
<th>Traits</th>
<th>LnRMSSD rp (SE)</th>
<th>LnRMSSDc rp (SE)</th>
<th>LnRMSSD rG (SE)</th>
<th>LnRMSSDc rG (SE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR</td>
<td>-0.56 (0.002)</td>
<td>-0.60 (0.02)</td>
<td>-0.54 (0.01)</td>
<td>-0.36 (0.002)</td>
</tr>
<tr>
<td>SBP</td>
<td>-0.10 (0.003)</td>
<td>-0.20 (0.03)</td>
<td>-0.08 (0.01)</td>
<td>-0.07 (0.003)</td>
</tr>
<tr>
<td>DBP</td>
<td>-0.07 (0.003)</td>
<td>-0.15 (0.03)</td>
<td>-0.04 (0.01)*</td>
<td>-0.05 (0.003)</td>
</tr>
<tr>
<td>MAP</td>
<td>-0.09 (0.003)</td>
<td>-0.18 (0.03)</td>
<td>-0.06 (0.01)</td>
<td>-0.06 (0.003)</td>
</tr>
<tr>
<td>PP</td>
<td>-0.08 (0.003)</td>
<td>-0.14 (0.03)</td>
<td>-0.07 (0.01)</td>
<td>-0.06 (0.003)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Traits</th>
<th>LnSDNN rp (SE)</th>
<th>LnSDNNc rp (SE)</th>
<th>LnSDNN rG (SE)</th>
<th>LnSDNNc rG (SE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR</td>
<td>-0.40 (0.002)</td>
<td>-0.53 (0.03)</td>
<td>-0.36 (0.01)</td>
<td>-0.15 (0.003)</td>
</tr>
<tr>
<td>SBP</td>
<td>-0.08 (0.003)</td>
<td>-0.16 (0.03)</td>
<td>-0.06 (0.01)</td>
<td>-0.04 (0.003)</td>
</tr>
<tr>
<td>DBP</td>
<td>-0.06 (0.003)</td>
<td>-0.13 (0.03)</td>
<td>-0.03 (0.01)*</td>
<td>-0.03 (0.003)</td>
</tr>
<tr>
<td>MAP</td>
<td>-0.07 (0.003)</td>
<td>-0.16 (0.03)</td>
<td>-0.05 (0.01)</td>
<td>-0.04 (0.003)</td>
</tr>
<tr>
<td>PP</td>
<td>-0.06 (0.003)</td>
<td>-0.10 (0.03)</td>
<td>-0.05 (0.01)</td>
<td>-0.03 (0.003)</td>
</tr>
</tbody>
</table>

Models were adjusted for age, age$^2$, sex, and BMI. BMI indicates body mass index; DBP, diastolic blood pressure; HR, heart rate; InRMSSD, log-transformed root mean square of successive differences; InRMSSDc, log-transformed corrected root mean square of successive differences; InSDNN, log-transformed SD of normal-to-normal intervals; InSDNNc, log-transformed corrected SD of normal-to-normal intervals; MAP, mean arterial pressure; PP, pulse pressure; rE, environmental correlation; rG, genetic correlation; rP, phenotypic correlation; and SBP, systolic blood pressure.

*Nonsignificant genetic correlations ($P>0.05$).

**Discussion**

In this study, we showed that genetic factors significantly influence the variance in HRV and BP. Our results also show significant negative genetic correlations between HRV and BP measures, which suggests shared genetic factors partly explain the inverse association between these traits.

In the present study, we found similar heritability estimates for RMSSD and SDNN as in the Framingham Heart Study$^{11}$ and in recent reports from the Oman Family
Our results were lower than heritability estimates from the Kibbutzim family study in Israel, 39% for SDNN and 41% for RMSSD. The possible explanation for a relatively higher heritability values in the Israel study might be due to an inclusion of more homogenous samples. Our heritability estimates for SDNN and RMSSD remained significant after taking into account the effect of mean heart rate on HRV measures. This finding confirms that the genetic influence in HRV measures is largely independent of the influence of heart rate. Our results also showed substantial heritability of BP measured in supine position ranging from 24.4% for PP to 30.3% for DBP. These findings are slightly higher than heritability estimates reported in previous family studies which might be due to the large sample size. A small study in Sweden reported that none of the BP measures were heritable and another small study conducted in the Seychelles reported a non-significant heritability for DBP but a higher one than we found for pulse pressure (h²=24.4%)18. However, both of these studies were likely underpowered, (N=260 and 314 participants, respectively). Only one family study from Nigeria reported a heritability estimate for MAP and found a slightly higher heritability compared to our study (36% versus 30%). Differences in heritability estimates could be varying between populations due to different ethnic backgrounds of study participants.

The present study shows consistently significant (from 0) and negative genetic correlations between HRV and BP, particularly with SBP and DBP. This is in line with previous findings from cross-sectional and prospective studies that reported lower HRV is associated with high BP. This confirms our hypothesis that shared genetic factors might also explain the negative associations between HRV and BP. In agreement with this, the genetic correlations using bivariate linkage disequilibrium score regression on genome-wide association study summary statistics for HRV and BP show largely consistent estimates. On the contrary, the Oman Family study recently reported a non-significant genetic correlation. However, the authors admittedly recognize that the sample size of their study might have been too small to detect the underlying genetic contributions.

A major strength of our study is that it constitutes the largest family study to date on the subject, providing ample power for precise estimates of heritability and genetic overlap. Unlike previous studies, we applied a recommended correction method to adjust the well-known effect of heart rate on HRV to re-calculate heritability estimates. Furthermore, familial effects were included in the analysis to minimize over-inflation of the heritability estimates due to the common environment shared by family members. Our study however acknowledges the following limitations. First, antihypertensive treatments might obscure familial contributions to BP.
variations\textsuperscript{35}. However, we adjusted the measured BP values by adding 15mmHg to measured SBP and 10mmHg to measured DBP level as recommended by Tobin and colleagues\textsuperscript{23}. This correction approximates pre-treatment BP values and may restore the correct population ranking of BP values to a large extent and optimize estimates of the genetic variance component. Second, because of a vast majority (96.5\%) of participants are of Caucasian ancestry the results of this study cannot be generalized to other ethnicities. Finally, our study was limited to time-domain parameters SDNN and RMSSD, because ultra-short ECG recordings are too short to assess frequency-domain HRV parameters\textsuperscript{1}.

To conclude, in this large family study, we showed that the contribution of genetic factors to the variance of HRV (ranging from 15.6\% to 17.9\%), and BP (ranging from 24.4\% to 30.3\%) in the general population are substantial. The significant negative genetic correlations between HRV and blood pressure indicate that genes (genetic pathways) for HRV and BP partially overlap.

**Perspectives**

This implies the need for more studies in the future to identify more genetic variants as the variance explained by known common single nucleotide polymorphisms discovered in previous genome-wide association studies is still low (0.9\%-2.3\% for HRV measures and 2.9\%-5.7\% for BP measures)\textsuperscript{27,30}. The negative genetic correlations between HRV and BP are in line with a causal effect of cardiac vagal control in the development of hypertension. However, some more discussion is warranted what the results may mean: 1) pleotropic genes; 2) causal effect or 3) reverse causation, meaning an increase in BP causes compensatory changes in cardiac autonomic nervous system activity that lead to reduced HRV. Mendelian randomization, a statistical approach to test the direction of causality in epidemiologic studies, may be considered in future studies to overcome this problem. If a causal effect were to be confirmed in future studies, this would have potential implications for prevention and treatment of hypertension.

**Acknowledgment**

The Lifelines Biobank initiative has been made possible by subsidy from the Dutch Ministry of Health, Welfare and Sport, the Dutch Ministry of Economic Affairs, the University Medical Center Groningen (UMCG the Netherlands), University Groningen and the Northern Provinces of the Netherlands. We are grateful for the services of the Lifelines Cohort Study and Biobank, the research support staffs, and all the study participants. We would also like to thank Dr. Arthur Gilmour for his help in running ASReml software.
Chapter 6

References


Heritability and the genetic correlation of heart rate variability and blood pressure in >29 000 families


